



Ronald M. Califre
Senior Vice President
Head, U.S. Operations
Research and Development

NOVARTIS INSTITUTE FOR BIOMEDICAL RESEARCH
Novartis Pharmaceuticals Corporation
One Health Plaza
East Hanover, New Jersey 07936-1080

Tel: (862) 778-2394
Fax: (973) 781-2407
Internet: ronald.califre@novartis.com

January 22, 2008

Dr. Thomas Thompson
U.S. Nuclear Regulatory Commission Region 1
Nuclear Materials Safety and Safeguards Branch
475 Allendale Road
King of Prussia, PA 19406-1415

*MS 16
P-7*

Re: Mail Control No. 141583

Dear Dr. Thompson,

03005357

Per your request, this letter is to apprise the Nuclear Regulatory Commission of the experience that our proposed interim Radiation Safety Officer, Mr. Richard Brack, has with the different by-product materials as authorized on the Novartis Pharmaceuticals Corporation (NPC) NRC radioactive material license 29-08978-02.

Mr. Brack has twelve years experience as a bench scientist working with the by-product materials listed on NPC's NRC radioactive material license and 5 years experience managing laboratory safety programs. The following is a detailed accounting of the specific training and experience that Mr. Brack has with the types of by-product materials that he will be managing.

During Mr. Brack's three years working for Memorial Sloan-Kettering Cancer Center he was thoroughly trained on the use of by-product material (radionuclides) related to his research work. This work included in situ end-labeling, in situ nick translations, Southern Blot Analysis and several other assays which involved the use of P-32, S-35 and I-125. Mr. Brack was also trained at NPC on the use of by-product material (radionuclides) for his work with cell-based assays, where tritium was used for screening thousands of compounds for the transplantation drug discovery program.

Mr. Brack has experience with, and has been trained on, the following: review of animal protocols where radioisotopes are used, radioisotope contamination monitoring, DOT/NRC/IATA radioactive material shipping regulations, radioactive analysis using radiotracer liquid scintillation analysis, personnel monitoring (bioassays and badges), radioisotope inventory management, ALARA practices, and radiation safety program administration.


141583

NMSS/RGN1 MATERIALS-002

Dr. Thomas Thompson
U.S. Nuclear Regulatory Commission
January 22, 2008
Page 2 of 2

Additionally, Mr. Brack is working under the guidance of the Head of HSE&BC, Gregory King, who was formerly the Novartis Radiation Safety Officer and is certified by the American Academy of Health Physics in the comprehensive practice of Health Physics. If you have any questions please contact Mr. Gregory King at 862-778-0495.

Sincerely,

A handwritten signature in black ink, appearing to read "Ronald M. Califre", is written over the typed name and title.

Ronald M. Califre
Senior Vice President
Research & Development Operations